cisplatin

P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2026 --> Jun 2027

P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026

P2, N=63, Completed, Washington University School of Medicine | Active, not recruiting --> Completed

P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed

Mechanistically, compared with Dio or DDP treatment alone, combined Dio and DDP treatment suppressed the MAPK signaling pathway, represented by reduced phosphorylation of JNK, ERK, and P38. These findings demonstrated that Dio potentiates the anticancer effects of DDP both in vitro and in vivo, indicating that Dio is a promising adjuvant for OC treatment.

BISDA displayed 48-h IC50 of 2.609 µg mL-1 in A549 cells, decreased viability compared to controls, and was less toxic than cisplatin while inducing apoptosis, G2/M cell cycle arrest, and inhibiting cancer cell migration...Principal component analysis showed that BISDA reprogrammed signaling through decoupling of the EGFR-mTOR axis from the TGFβ-AKT1-MAPK3-HSP90 cluster, indicative of a global rewiring of pathways. These results suggest that BISDA may serve as a multifaceted inhibitor for treating LUAD, acting in an antiproliferative capacity through apoptosis induction while also preventing signaling pathways associated with resistance.

In vivo, exosomal NEAT1 promoted tumor growth in DDP-treated xenografts, while NEAT1 knockdown reversed this effect and restored p53 pathway activity. Collectively, our work unveils a novel TAM-exosome-NEAT1-MAD1L1/p53 signaling axis that drives cisplatin resistance in lung adenocarcinoma, highlighting NEAT1 and its intercellular delivery as potential therapeutic targets to overcome chemoresistance.

DHCR24 expression and function were systematically evaluated using cisplatin-resistant cell lines (A2780/DDP, SKOV3/DDP), patient-derived primary cells, xenograft models, and clinical specimens through molecular biology techniques, immunohistochemistry, and functional assays...Furthermore, activated STAT3 transcriptionally upregulated DHCR24 expression, establishing a positive feedback loop that perpetuates the chemoresistant phenotype. DHCR24 drives chemoresistance through a cholesterol-dependent circuit that stabilizes drug efflux pumps and activates pro-survival signaling, identifying DHCR24 as a promising therapeutic target for overcoming chemotherapy resistance in ovarian cancer.

In a cisplatin-induced rat emesis model, IJ-ODW reduced kaolin intake by 18.3% (p 10 h)...STATEMENT OF SIGNIFICANCE: This study reports the rational design of an anisotropic, excipient-free buccal wafer, which overcomes the fundamental "speed-stability paradox" in mucosal delivery through its engineered bilayered architecture. By integrating ultrafast adhesion with sustained, polarity-selective release and active neuro-immune modulation, this material platform provides a scalable and dysphagia-tailored therapeutic strategy, advancing the design of multifunctional biomaterials for complex clinical needs.

P3, N=442, Not yet recruiting, Sun Yat-sen University

P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026

P1/2, N=32, Not yet recruiting, Rgene Corporation | Trial completion date: Dec 2027 --> Dec 2028